# Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

> **NCT03164993** · PHASE2 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 68 (actual)

## Conditions studied

- Cancer, Breast
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Cyclophosphamide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03164993
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2023-04-25
- **Final completion:** 2023-09-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164993, "Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03164993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*